Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors,...
-
Oslo, Norway, 6 June 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces formal...
-
Oslo, Norway, 18 May 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors,...
-
Proof of concept study of sequential ONCOS-102 then pembrolizumab treatment in patients with advanced melanoma refractory to check-point inhibitors Oslo 10 May 2017: Targovax ASA ("Targovax" or...
-
Oslo, Norway, 8 May 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will be hosting...
-
Reference is made to annual general meeting of Targovax ASA's (the "Company") on 5 April 2017 (the "AGM") where all the board members were re-elected. At the annual general meeting of the Company the...
-
Oslo, Norway, 25 April 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces...
-
First patient enrolled in a Phase Ib trial in patients with locally recurrent RAS-mutated rectal cancer Oslo, 20 April 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical...
-
Oslo, Norway, 19 April 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2017 results...
-
Oslo, Norway, 6 April 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors,...